NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $5.66 -0.06 (-0.96%) As of 11:54 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LENZ Therapeutics Stock (NASDAQ:LENZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LENZ Therapeutics alerts:Sign Up Key Stats Today's Range$5.57▼$5.7050-Day Range$4.88▼$7.9952-Week Range$4.68▼$50.40Volume135,493 shsAverage Volume957,221 shsMarket Capitalization$177.60 millionP/E RatioN/ADividend YieldN/APrice Target$29.80Consensus RatingHold Company Overview LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. Read More LENZ Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreLENZ MarketRank™: LENZ Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 507th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingLENZ Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialLENZ Therapeutics has a consensus price target of $29.80, representing about 421.6% upside from its current price of $5.71.Amount of Analyst CoverageLENZ Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about LENZ Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($4.63) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LENZ Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENZ Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted41.25% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 10.46, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently increased by 13.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentLENZ Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for LENZ Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows10 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.30% of the stock of LENZ Therapeutics is held by insiders.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LENZ Stock News HeadlinesLENZ Therapeutics Stock Dividends | NASDAQ:LENZ | BenzingaJuly 12, 2026 | benzinga.comLENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth AssumptionsJuly 11, 2026 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 30 at 1:00 AM | Porter & Company (Ad)Analysts Are Neutral on These Healthcare Stocks: LENZ Therapeutics (LENZ), Agilent (A)July 10, 2026 | theglobeandmail.comLENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV CampaignJuly 6, 2026 | quiverquant.comQLENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of PresbyopiaJuly 6, 2026 | globenewswire.comLENZ Therapeutics Insider Trading Activity | NASDAQ:LENZ | BenzingaJune 28, 2026 | benzinga.comLENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New ZealandJune 25, 2026 | finance.yahoo.comSee More Headlines LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.00 on January 1st, 2026. Since then, LENZ stock has decreased by 64.3% and is now trading at $5.7130. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) issued its earnings results on Monday, May, 11th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.10) by $0.22. The company had revenue of $1.90 million for the quarter, compared to analysts' expectations of $1.76 million. LENZ Therapeutics had a negative trailing twelve-month return on equity of 46.82% and a negative net margin of 519.30%. Read the conference call transcript. When did LENZ Therapeutics IPO? LENZ Therapeutics (LENZ) raised $224 million in an IPO on Thursday, June 24th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENZ Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings5/11/2026Today7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 LENZ's financial health is in the Red zone, according to TradeSmith. LENZ has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployees110Year Founded2013Price Target and Rating Average Price Target for LENZ Therapeutics$29.80 High Price Target$50.00 Low Price Target$12.00 Potential Upside/Downside+432.7%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.13 million Net Margins-519.30% Pretax Margin-516.91% Return on Equity-46.82% Return on Assets-43.32% Debt Debt-to-Equity RatioN/A Current Ratio10.40 Quick Ratio10.26 Sales & Book Value Annual Sales$19.09 million Price / Sales9.19 Cash FlowN/A Price / Cash FlowN/A Book Value$9.09 per share Price / Book0.62Miscellaneous Outstanding Shares31,350,000Free Float28,752,000Market Cap$175.37 million OptionableN/A Beta0.62 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:LENZ) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX just minted 4,400 millionairesSpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times...The Oxford Club | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBNZI Is Building an AI Growth EngineBanzai International (NASDAQ: BNZI) just earned a Zacks Rank 2 (Buy) upgrade, reflecting rising confidence in ...Huge Alerts | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LENZ Stock Alerts